Study of Acalabrutinib in Chinese Adult Subjects with Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or other B-cell Malignancies

Trial Identifier: D8220C00007
Sponsor: AstraZeneca
NCTID:: NCT03932331
Start Date: April 2020
Primary Completion Date: June 2022
Study Completion Date: December 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN beijing, CN, 100191
CN Beijing, CN, 100142
CN Beijing, CN, 100044
CN Changchun, CN, 130021
CN Changsha, CN, 410008
CN changzhou, CN, 272100
CN Chengdu, CN, 610041
CN fuzhou, CN
CN Haikou, CN, 570311
CN Hangzhou, CN, 310003
CN Hangzhou, CN, 310022
CN Harbin, CN, 150049
CN Hefei, CN, 230031
CN Hohhot, CN, 10050
CN Nanchang, CN, 330006
CN Nanjing, CN, 210029
CN Shanghai, CN, 200032
CN Shijiazhuang, CN, 050020
CN suzhou, CN, 215006
CN tianjin, CN, 300020
CN Tianjin, CN, 300060
CN Urumqi, CN, 830054
CN Xining, CN, 810007
CN Zhengzhou, CN, 450008
CN Zhengzhou, CN, 450052